Trial Profile
An Open-label, Single-arm, Phase II Clinical Study of Anti-PD-1 Antibody GB226 in Treatment of Relapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma (ASPS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Mar 2023
Price :
$35
*
At a glance
- Drugs Geptanolimab (Primary)
- Indications Alveolar soft part sarcoma
- Focus Therapeutic Use
- Acronyms GB226
- Sponsors Genor Biopharma
- 02 Mar 2021 Planned End Date changed from 30 Dec 2020 to 30 Dec 2022.
- 02 Mar 2021 Planned primary completion date changed from 1 Aug 2020 to 1 Aug 2021.
- 12 Oct 2020 Status changed from recruiting to completed.